Tauriga Sciences, Inc.’s Vendor Registration Approved by Miami International Airport (MIA)
Tauriga Sciences (TAUG) has secured approval to become a Registered Vendor at Miami International Airport (MIA) for selling its Tauri-Gum™ product line. The Company is partnering with a South Florida distribution firm to target select U.S. airports. With the upcoming launch of an enhanced Tauri-Gum™ product line (9 SKUs), Tauriga aims to capitalize on strong sales trends in airport retail. Additionally, an updated Product Catalogue with wholesale pricing has been completed, and meetings are scheduled with potential national buyers and distributors.
- Approval as a Registered Vendor at Miami International Airport enhances distribution channels.
- Plans to launch an enhanced Tauri-Gum™ product line with nine SKUs.
- Strong sales potential for Tauri-Gum™ in airport terminals.
- None.
The Company Will Focus on Selling its Tauri-Gum™ Product Line Through MIA Concessions
NEW YORK, NY, June 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a New York based diversified Life Sciences Company, today obtained approval from Miami International Airport (Code: MIA) to become a Registered Vendor. Specifically, the Company has been registered through the Miami-Dade County Supplier Portal, for access to MIA Concessions. The MIA Concession (Airport Department) procures concession retail, food & beverage, snacks, and services through a solicitation (“bidder”) process.
The Company is working closely with a South Florida based Airport Distribution firm, to sell its flagship Tauri-Gum™ product line to select U.S. based airports. With the imminent commercial launch of its enhanced Tauri-Gum™ product line (9 SKUs), the Company is confident in its ability to compete for the business of air travelers. Chewing gum products generate strong levels of sales within airport terminals (stores and kiosks).
In other news, the Company has completed its updated Product Catalogue, which includes wholesale pricing (for large quantity purchase orders). The Company can confirm a number of upcoming scheduled meetings, with potential Buyers & Distributors (some of which have National footprints).
Over the coming days, the Company expects to disclose several important catalysts. Owing to its strong balance sheet (cash & marketable securities), the Company has the ability to both capitalize on multiple opportunities and enter into material Agreements/Partnerships.
Credentials Provided by Miami-Dade County:
Vendor Name: Tauriga Sciences, Inc.
Vendor ID: B000009271
ABOUT TAURIGA SCIENCES INC.
Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives. The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment. The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant), (Vitamin C + Zinc Infused Tauri-Gum™ Flavor: Pear Bellini), (Caffeine Infused Tauri-Gum™ Flavor: Cherry Lime Rickey), & (Vitamin D3 Infused Tauri-Gum™ Flavor: Golden Raspberry). The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com
Complementary to the Company’s retail business, is its ongoing Pharmaceutical Development initiative. This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 22, 2021, the Company announced that it had Converted its U.S. Provisional Patent Application (filed on March 17, 2020) into a U.S. Non-Provisional Patent Application. The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company's clinical development efforts.
The Company is headquartered in Wappingers Falls, New York. In addition, the Company operates two full time E-Commerce fulfillment centers: one located in Montgomery, Texas and the other in Brooklyn, New York.
DISCLAIMER -- Forward-Looking Statements
This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other periodic filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.
Contact:
Tauriga Sciences, Inc.
4 Nancy Court, Suite 4
Wappingers Falls, NY 12590
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
cell # (917) 796 9926
Company Instagram: @taurigum
Personal Instagram: @sethsms47
Twitter: @SethMShaw
Corp. Website: www.tauriga.com
E-Commerce Website: www.taurigum.com
FAQ
What is Tauriga Sciences (TAUG) focusing on at Miami International Airport?
How many SKUs are included in the upcoming Tauri-Gum™ product line?
What type of partnerships is Tauriga Sciences pursuing?
Where can Tauri-Gum™ be sold aside from Miami International Airport?
